Synergistic Effect of Lenvatinib and Chemotherapy in Hepatocellular Carcinoma Using Preclinical Models

References

• Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2022. CA. 2022;72(1):7–33. doi:10.3322/caac.21708
   Web of Science ®Google Scholar
• Chung AS, Mettlen M, Ganguly D, et al. Immune checkpoint inhibition is safe and effective for liver cancer prevention in a mouse model of hepatocellular carcinoma. Cancer Prev Res. 2020;13(11):911–922. doi:10.1158/1940-6207.CAPR-20-0200
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Di Federico A, et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand? Front Oncol. 2021;11. doi:10.3389/fonc.2021.803133
   Web of Science ®Google Scholar
• Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31(4):361–369. doi:10.1080/13543784.2022.2009455
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci A, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol. 2021;15(11):1245–1251. doi:10.1080/17474124.2021.1973431
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/s0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:175883592093693. doi:10.1177/1758835920936932
   Web of Science ®Google Scholar
• Gao Q, Wang Z-C, Duan M, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. Gastroenterology. 2017;152:1. doi:10.1053/j.gastro.2016.09.008
   Web of Science ®Google Scholar
• Levatić J, Salvadores M, Fuster-Tormo F, Supek F. Mutational signatures are markers of drug sensitivity of cancer cells. Nat Commun. 2022;13(1):2926. doi:10.1038/s41467-022-30582-3
   PubMed Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747. doi:10.1155/2014/638747
   PubMedGoogle Scholar
• Okamoto K, Ikemori-Kawada M, Jestel A, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett. 2015;6(1):89–94. doi:10.1021/ml500394m
   PubMed Web of Science ®Google Scholar
• Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–2992. doi:10.1200/JCO.19.02627
   PubMed Web of Science ®Google Scholar
• Taylor MH, Lee C-H, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020;38(11):1154–1163. doi:10.1200/JCO.19.01598
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, Phase 2 trial. Lancet Oncol. 2020;21(8):1057–1065. doi:10.1016/S1470-2045(20)30271-0
   PubMed Web of Science ®Google Scholar
• Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501–3508. doi:10.1200/JCO.2012.44.5643
   PubMed Web of Science ®Google Scholar
• Hou Z, Liu J, Jin Z, et al. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends. 2022;16(1):31–45. doi:10.5582/bst.2022.01044
   PubMed Web of Science ®Google Scholar
• Benson A, D’Angelica M, Abbott D, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. JNCCN. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022
   Google Scholar
• Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013. doi:10.1158/2159-8290.CD-14-0001
   PubMed Web of Science ®Google Scholar
• Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20(1):206. doi:10.1186/s12967-022-03405-8
   PubMed Web of Science ®Google Scholar
• Han S, Wu J. Three-dimensional (3D) scaffolds as powerful weapons for tumor immunot herapy. Bioact Mater. 2022;17:300–319. doi:10.1016/j.bioactmat.2022.01.020
   PubMed Web of Science ®Google Scholar
• Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346(6216):1480–1486. doi:10.1126/science.1254721
   PubMed Web of Science ®Google Scholar
• Byrne AT, Alférez DG, Amant F, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17(4):254–268. doi:10.1038/nrc.2016.140
   PubMed Web of Science ®Google Scholar
• Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nature Rev. 2022;19(11):719–732. doi:10.1038/s41571-022-00682-6
   Web of Science ®Google Scholar
• Mohammed A, Shoemaker RH, Sei S. Cancer immunoprevention: challenges and potential opportunities for use of immune checkpoint inhibitors. Cancer Prev Res. 2020;13(11):897–900. doi:10.1158/1940-6207.CAPR-20-0432
   PubMed Web of Science ®Google Scholar
• Llovet J, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Reagan‐Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2007;22(3):659–661. doi:10.1096/fj.07-9574LSF
   PubMed Web of Science ®Google Scholar
• Mattei F, Kato Y, Tabata K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. doi:10.1371/journal.pone.0212513
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Matsushima T, Kawano S, et al. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci. 2014;105(6):723–730. doi:10.1111/cas.12409
   PubMed Web of Science ®Google Scholar
• Ivanova E, Kuraguchi M, Xu M, et al. Use of patient-derived tumor organotypic spheroids to identify combination therapies for mutant non-small cell lung cancer. Clin Cancer Res. 2020;26(10):2393–2403. doi:10.1158/1078-0432.CCR-19-1844
   PubMed Web of Science ®Google Scholar
• Yu M, Selvaraj SK, Liang-Chu MMY, et al. A resource for cell line authentication, annotation and quality control. Nature. 2015;520(7547):307–311. doi:10.1038/nature14397
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Sperandio R, Pestana R, Miyamura B, Kaseb A. Hepatocellular carcinoma immunotherapy. Annu Rev Med. 2022;73:267–278. doi:10.1146/annurev-med-042220-021121
   PubMed Web of Science ®Google Scholar
• Hou Y, Guo H, Cao C, et al. Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas. Cell Res. 2016;26(3):304–319. doi:10.1038/cr.2016.23
   PubMed Web of Science ®Google Scholar
• Yang F, Hilakivi-Clarke L, Shaha A, et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023. doi:10.1097/hep.0000000000000005
   Web of Science ®Google Scholar
• Zheng H, Pomyen Y, Hernandez MO, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018;68(1):127–140. doi:10.1002/hep.29778
   PubMed Web of Science ®Google Scholar
• Goyal L, Zheng H, Abrams TA, et al. A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2019;25(1):80–89. doi:10.1158/1078-0432.CCR-18-0847
   PubMed Web of Science ®Google Scholar
• Honkala A, Malhotra SV, Kummar S, Junttila MR. Harnessing the predictive power of preclinical models for oncology drug development. Nat Rev Drug Discov. 2021. doi:10.1038/s41573-021-00301-6
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.018
   PubMed Web of Science ®Google Scholar
• Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017;32:1. doi:10.1016/j.ccell.2017.05.009
   PubMed Web of Science ®Google Scholar
• Ma L, Heinrich S, Wang L, et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun. 2022;13(1):7533. doi:10.1038/s41467-022-35291-5
   PubMed Web of Science ®Google Scholar
• Xin H, Wang K, Hu G, et al. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. PLoS One. 2014;9(1):e85308. doi:10.1371/journal.pone.0085308
   PubMed Web of Science ®Google Scholar
• Kim J, Koo B-K, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21(10):571–584. doi:10.1038/s41580-020-0259-3
   PubMed Web of Science ®Google Scholar
• Hu B, Li H, Guo W, et al. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int J Cancer. 2020;146(6):1606–1617. doi:10.1002/ijc.32564
   PubMed Web of Science ®Google Scholar